Nilotinib Stada (Nilotinib)

Nilotinib acts on BCR‑ABL driven leukemias, providing targeted inhibition of malignant cell proliferation.

• Chronic Myeloid Leukemia (CML) – chronic phase: Improves hematologic and cytogenetic response, slowing disease progression.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): Contributes to remission when used in combination therapy.
• BCR‑ABL positive leukemias: Targets the underlying kinase driving malignant cell growth, offering a disease‑modifying option.

• Nilotinib selectively inhibits the BCR‑ABL tyrosine kinase by binding to its ATP‑binding site, blocking downstream signaling pathways that drive proliferation and survival of malignant cells. This inhibition also affects related kinases such as c‑KIT and PDGFR, further reducing oncogenic signaling and inducing apoptosis in affected leukemic cells.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: loose stools often occurring early in therapy.
• Rash: skin erythema or pruritus.
• Fatigue: generalized tiredness.
• Headache: transient cranial discomfort.
• Myalgia: muscle aches.

Serious or Rare Side Effects

• QT interval prolongation: may predispose to cardiac arrhythmias.
• Pancreatitis: inflammation of the pancreas requiring medical attention.
• Severe hepatic injury: elevated liver enzymes or hepatitis.
• Neutropenia: marked reduction in neutrophil count.
• Stevens‑Johnson syndrome: severe skin and mucosal reaction.
• Cardiovascular events: myocardial ischemia or thromboembolic episodes.

Patients should be monitored for cardiac, hepatic and hematologic safety before and during treatment.

• ECG monitoring: assess QT interval regularly.
• Liver function tests: evaluate baseline and periodic ALT/AST levels.
• Blood counts: monitor neutrophils and platelets for cytopenias.
• Drug interactions: avoid strong CYP3A4 inhibitors unless medically necessary.
• Pregnancy and lactation: contraindicated unless benefits outweigh risks; discuss with physician.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nilotinib may interact with several co‑administered medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase Nilotinib plasma concentrations.
• QT‑prolonging agents (e.g., amiodarone, fluoroquinolones): additive risk of cardiac arrhythmia.
• Antacids containing aluminum or magnesium: reduce absorption if taken simultaneously.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampicin, St. John’s wort): may lower Nilotinib exposure.
• Proton pump inhibitors: may modestly affect gastric pH and drug uptake.
• Concomitant anticoagulants: monitor for bleeding if hepatic function is impaired.